^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Nectin-4-targeted antibody-drug conjugate

    Related drugs:
    6d
    DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Bavencio (avelumab) • Padcev (enfortumab vedotin-ejfv)
    7d
    A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder (clinicaltrials.gov)
    P2, N=240, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    7d
    Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy. (PubMed, Urol Oncol)
    NECTIN-4 expression differs by tissue type, limiting prognostic value and supporting site-specific biomarker assessment in BC.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 expression
    |
    Padcev (enfortumab vedotin-ejfv)
    9d
    BAT-8007-001-CR: To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=93, Terminated, Bio-Thera Solutions | N=250 --> 93 | Trial completion date: Jul 2026 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Aug 2025; Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BAT8007
    9d
    A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=149, Recruiting, Samsung Bioepis Co., Ltd.
    New P1 trial • First-in-human
    9d
    SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=406, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel
    10d
    Port-Site Seeding of Urothelial Carcinoma After Robotic-Assisted Radical Prostatectomy Accompanied With Elevated Serum Levels of Carbohydrate Antigen 19-9: A Case Report. (PubMed, Case Rep Urol)
    Cancer progression with the elevation of serum CA19-9 was observed during subsequent avelumab therapy, and enfortumab vedotin therapy was initiated. RARP for patients with a past history of bladder tumor presents a risk of dissemination of UC due to urine leakage. Thorough examination for UC before RARP is recommended.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Bavencio (avelumab) • Padcev (enfortumab vedotin-ejfv)
    14d
    New and Emerging Drug Reactions. (PubMed, Dermatol Clin)
    In this article, we discuss the clinical and histopathologic findings of cutaneous adverse reactions to newer medications, including those recently approved to treat inflammatory skin diseases, such as dupilumab for atopic dermatitis and IL-12/-23 and IL-23 specific inhibitors for psoriasis, as well as those with oncologic indications, including immune checkpoint inhibitors, mogamulizumab, and enfortumab vedotin.
    Review • Journal
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    Padcev (enfortumab vedotin-ejfv) • Poteligeo (mogamulizumab-kpkc) • Dupixent (dupilumab)
    15d
    Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer (clinicaltrials.gov)
    P1/2, N=132, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Padcev (enfortumab vedotin-ejfv)
    16d
    A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=398, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • pemetrexed • topotecan • SHR-A2102
    26d
    Urothelial Carcinoma of the Bladder with a Single Pancreatic Metastasis: A Case Report. (PubMed, Reports (MDPI))
    The patient was referred for systemic therapy with immune checkpoint inhibitors and Enfortumab Vedotin...EUS-guided biopsy with immunohistochemistry is essential to distinguish secondary lesions from primary pancreatic tumors. Accurate diagnosis is crucial to guide systemic therapy, particularly with emerging immunotherapy and antibody-drug conjugates.
    Journal
    |
    GATA3 (GATA binding protein 3)
    |
    Padcev (enfortumab vedotin-ejfv)
    26d
    A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    MK-3120